Multicenter trial of intravenous Anisoylated Plasminogen Streptokinase Activator Complex (APSAC) in acute myocardial infarction: Effects on infarct size and left, ventricular function
- 1 April 1989
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 13 (5), 988-997
- https://doi.org/10.1016/0735-1097(89)90249-0
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarctionThe American Journal of Cardiology, 1988
- Thrombolytic Therapy: Current StatusNew England Journal of Medicine, 1988
- Systemic effects of thrombolytic drugs in acute myocardial infarction: Comparison of intravenous APSAC (BRL 26921) and intracoronary streptokinaseFibrinolysis, 1987
- Anisoylated Plasminogen Streptokinase Activator Complex (APSAC)Drugs, 1987
- An Interim Report of the Efficacy and Safety of Anisoylated Plasminogen Streptokinase Activator Complex (APSAC)1Drugs, 1987
- Intravenous Anisoylated Plasminogen Streptokinase Activator Complex versus Intravenous Streptokinase in Evolving Myocardial InfarctionDrugs, 1987
- Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex.BMJ, 1986
- Clinical effects and kinetic properties of intravenous APSAC — anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarctionInternational Journal of Cardiology, 1986
- Coronary thrombolysis with intravenous anisoylated plasminogen-streptokinase complex BRL 26921.Heart, 1985
- Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapyNature, 1981